“…In this study, we also performed an explorative analysis on the distribution of non-responder patients when our cohort was stratified for anti- TNFα drugs, and we found a lower response in the case of Infliximab, also depending on the higher number of patients treated with this drug. The role of genetic factors for the lack of therapeutic response to anti- TNFα agents was previously suggested in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), juvenile idiopathic arthritis (JIA), and Sjögren’s syndrome, as well as in inflammatory bowel disease, in particular Crohn’s disease (CD), but also in Wegener’s granulomatosis and sarcoidosis [ 4 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 ].…”